World's Best Scientists 2026 revealed!
Michael W. Deininger

Michael W. Deininger

D-Index & Metrics

Medicine

D-Index
113
Citations
71290
World Ranking
4837
National Ranking
2620

Overview

Michael W. Deininger is affiliated with the University of Utah in the United States and has made substantial contributions to the field of medicine, particularly in hematology. Their research spans multiple subfields including hematology, genetics, rheumatology, immunology, and molecular biology.

The scientist's primary research topics include chronic myeloid leukemia treatments and chronic lymphocytic leukemia research. Their work also covers eosinophilic disorders and syndromes, mast cells and histamine, acute myeloid leukemia research, acute lymphoblastic leukemia research, as well as click chemistry and its applications.

Their notable recent papers include:

  • Chronic Myeloid Leukemia, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology (2020), Journal of the National Comprehensive Cancer Network
  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia (2020), Leukemia
  • Integrative analysis of drug response and clinical outcome in acute myeloid leukemia (2022), Cancer Cell
  • Chronic Myeloid Leukemia: Modern therapies, current challenges and future directions (2021), Blood Reviews
  • Precision medicine treatment in acute myeloid leukemia using prospective genomic profiling: feasibility and preliminary efficacy of the Beat AML Master Trial (2020), Nature Medicine

Frequent coauthors collaborating with Michael W. Deininger include Jorge E. Cortés, Michael J. Mauro, Daniel J. DeAngelo, Andreas Hochhaus, and Jason Gotlib. These collaborations reflect a strong network within the hematology research community.

The venues in which they regularly publish research include Blood, Clinical Lymphoma Myeloma & Leukemia, Leukemia, Journal of Clinical Oncology, and HemaSphere. This demonstrates an engagement with leading journals dedicated to hematology and oncology research.

Best Publications

  • Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia

    Brian J. Druker;François Guilhot;Stephen G. O'brien;Insa Gathmann

  • European LeukemiaNet recommendations for the management of chronic myeloid leukemia: 2013

    Michele Baccarani;Michael W. Deininger;Gianantonio Rosti;Andreas Hochhaus

  • The molecular biology of chronic myeloid leukemia

    Michael W. N. Deininger;John M. Goldman;Junia V. Melo

  • A Double-Blind, Placebo-Controlled Trial of Ruxolitinib for Myelofibrosis

    Srdan Verstovsek;Ruben A. Mesa;Jason Gotlib;Richard S. Levy

  • Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European LeukemiaNet

    Michele Baccarani;Giuseppe Saglio;John Goldman;Andreas Hochhaus

  • Chronic Myeloid Leukemia: An Update of Concepts and Management Recommendations of European LeukemiaNet

    Michele Baccarani;Jorge Cortes;Fabrizio Pane;Dietger Niederwieser

  • Imatinib induces hematologic and cytogenetic responses in patients with chronic myelogenous leukemia in myeloid blast crisis: results of a phase II study

    Charles L. Sawyers;Andreas Hochhaus;Eric Feldman;John M. Goldman

  • The development of imatinib as a therapeutic agent for chronic myeloid leukemia

    Michael Deininger;Elisabeth Buchdunger;Elisabeth Buchdunger;Elisabeth Buchdunger;Brian J. Druker;Brian J. Druker;Brian J. Druker

  • Imatinib induces durable hematologic and cytogenetic responses in patients with accelerated phase chronic myeloid leukemia: results of a phase 2 study.

    Moshe Talpaz;Richard T. Silver;Brian J. Druker;John M. Goldman

  • AP24534, a Pan-BCR-ABL Inhibitor for Chronic Myeloid Leukemia, Potently Inhibits the T315I Mutant and Overcomes Mutation-Based Resistance

    Thomas O'Hare;Thomas O'Hare;William C. Shakespeare;Xiaotian Zhu;Christopher A. Eide;Christopher A. Eide

  • In vitro activity of Bcr-Abl inhibitors AMN107 and BMS-354825 against clinically relevant imatinib-resistant Abl kinase domain mutants.

    Thomas O'Hare;Denise K. Walters;Eric P. Stoffregen;Taiping Jia

  • A Phase 2 Trial of Ponatinib in Philadelphia Chromosome–Positive Leukemias

    Jorge E. Cortes;D. W. Kim;J. Pinilla-Ibarz;P. Le Coutre

  • European LeukemiaNet 2020 recommendations for treating chronic myeloid leukemia

    Andreas Hochhaus;Michele Baccarani;Richard T. Silver;Charles A. Schiffer

  • Long-Term Outcomes of Imatinib Treatment for Chronic Myeloid Leukemia

    Andreas Hochhaus;Richard A. Larson;François Guilhot;Jerald P. Radich

  • Functional genomic landscape of acute myeloid leukaemia

    Jeffrey W. Tyner;Cristina E. Tognon;Cristina E. Tognon;Daniel Bottomly;Beth Wilmot

  • Monitoring CML patients responding to treatment with tyrosine kinase inhibitors: review and recommendations for harmonizing current methodology for detecting BCR-ABL transcripts and kinase domain mutations and for expressing results

    Timothy P Hughes;Michael W Deininger;Andreas Hochhaus;Susan Branford

  • Selection and characterization of BCR-ABL positive cell lines with differential sensitivity to the tyrosine kinase inhibitor STI571: diverse mechanisms of resistance

    François Xavier Mahon;Michael W. N. Deininger;Beate Schultheis;Jérome Chabrol

  • Human chronic myeloid leukemia stem cells are insensitive to imatinib despite inhibition of BCR-ABL activity

    Amie S. Corbin;Amie S. Corbin;Anupriya Agarwal;Marc Loriaux;Jorge Cortes

  • The Tyrosine Kinase Inhibitor CGP57148B Selectively Inhibits the Growth of BCR-ABL–Positive Cells

    Michael W.N. Deininger;John M. Goldman;Nicholas Lydon;Junia V. Melo

  • Ponatinib in Refractory Philadelphia Chromosome–Positive Leukemias

    Jorge E Cortes;Hagop M Kantarjian;Neil P. Shah;Dale Bixby

Frequent Co-Authors

Brian J. Druker
Brian J. Druker Oregon Health & Science University
Jorge E. Cortes
Jorge E. Cortes Augusta University
Moshe Talpaz
Moshe Talpaz University of Michigan–Ann Arbor
Andreas Hochhaus
Andreas Hochhaus Friedrich Schiller University Jena
Hagop M. Kantarjian
Hagop M. Kantarjian The University of Texas MD Anderson Cancer Center
Neil P. Shah
Neil P. Shah University of California, San Francisco
Timothy P. Hughes
Timothy P. Hughes South Australian Health and Medical Research Institute
Michele Baccarani
Michele Baccarani University of Bologna
Francois Guilhot
Francois Guilhot Grenoble Alpes University
Carlo Gambacorti-Passerini
Carlo Gambacorti-Passerini University of Milano-Bicocca

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Pursuing a medical career in the USA isn't limited to becoming a doctor. There are diverse, flexible pathways available, including online degrees and alternative healthcare roles. For example, those with a non-nursing background interested in advanced nursing may consider online direct entry msn programs. These accelerated options let you transition into nursing at a higher level with efficiency.

If you’re seeking a more accessible start, researching the easiest rn program could help you enter the nursing profession with less competitive barriers. Some prospective nurses may prefer institutions that simplify admissions—schools where you can find a nursing school no entrance exam policy, removing the need for lengthy standardized tests.

The healthcare field also offers vital non-clinical roles. Interested in the administrative side? Consider training through medical billing and coding schools that accept financial aid, which help support hospitals and clinics behind the scenes. Each of these pathways provides valuable alternatives for individuals passionate about making a difference in healthcare.

Best Scientists Citing Michael W. Deininger

Trending Scientists

Recently Published Articles